Key Performance
More- Earnings Score: 53
- Momentum Score: 22
- True Yield: N/A
- Financial Health Score: 0
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Rosen Law Firm has filed a class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that the company made false and misleading statements regarding adequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented its business operations and prospects. Investors have until November 30, 2026 to move the court to serve as lead plaintiff.
10/02/2026, 2:48 PM • GlobeNewswire
A class action lawsuit has been filed against Anavex Life Sciences Corp. alleging securities fraud. The complaint claims the company made false statements about its business operations, lacked adequate internal controls, and understated regulatory challenges related to misconduct by former CEO Christopher Missling. The class period covers November 26, 2025 to August 28, 2026, and investors have until November 30, 2026 to request lead plaintiff status.
10/01/2026, 10:00 AM • GlobeNewswire
A securities class action lawsuit has been filed against Anavex Life Sciences Corp. (AVXL) for allegedly failing to disclose inadequate internal controls and regulatory challenges stemming from former CEO misconduct. The lawsuit covers securities purchased between November 26, 2025 and August 28, 2026. Investors have until November 30, 2026 to file as lead plaintiffs.
09/30/2026, 1:53 PM • GlobeNewswire
Rosen Law Firm has filed a securities class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges the company made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented its business operations and prospects. Investors have until November 30, 2026 to move the court to serve as lead plaintiff.
09/29/2026, 9:59 PM • GlobeNewswire
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
Anavex Life Sciences Corp. (AVXL) announced it has regained compliance with Nasdaq listing rules after filing outstanding Form 10-Qs for Q2 and Q3 2026. The company will host a conference call on September 9, 2026, where Interim CEO Terrie Kellmeyer will discuss clinical development strategy and priorities, with focus on Alzheimer's Disease programs.
09/08/2026, 8:00 AM • GlobeNewswire
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company
PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.
09/03/2026, 5:46 PM • GlobeNewswire
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Anavex Life Sciences announced it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing outstanding Form 10-Q filings for Q2 and Q3 2026 on August 28, 2026. The clinical-stage biopharmaceutical company, focused on CNS disease treatments, continues to advance its three core clinical development programs with emphasis on Alzheimer's disease.
09/02/2026, 4:00 PM • GlobeNewswire
The Schall Law Firm is investigating Anavex Life Sciences Corp. for potential securities law violations related to false or misleading statements. The investigation was triggered by the company's November 14, 2025 announcement of a negative trend vote from the European Medicines Agency's Committee for Medicinal Products for Human Use on the Marketing Authorisation Application for blarcamesine, which caused the stock to plummet over 35.9% on the same day.
12/24/2025, 10:30 AM • GlobeNewswire
The Schall Law Firm is investigating potential securities law violations by Anavex Life Sciences after the company received a negative trend vote from the European Medicines Agency on its blarcamesine marketing application, causing a significant stock price drop.
12/03/2025, 7:39 PM • Benzinga
Anavex Life Sciences Crashes as EMA Setback Sparks Doubts on Lead Alzheimer Drug
Anavex Life Sciences experienced a significant stock decline after receiving a negative trend vote from the European Medicines Agency regarding its Alzheimer's drug blarcamesine, causing shares to plummet approximately 50% in premarket trading.
11/14/2025, 9:36 AM • Investing
Market report analyzes the emerging disease-modifying therapies (DMTs) for Alzheimer's disease, highlighting market potential after lecanemab's FDA approval in 2023 and forecasting market trends through 2030.
08/05/2025, 4:26 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/01/2026
Company Profile
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.